Principal Active High Yield ETF

19.19

-0.0101-0.05%

Volume:30.97K

Turnover:594.07K

Market Cap:484.54M

PE:- -

High:19.20

Open:19.19

Low:19.17

Close:19.20

52wk High:19.48

52wk Low:17.88

Shares:25.25M

Float Shares:25.25M

Volume Ratio:0.85

T/O Rate:0.12%

Dividend:1.39

Dividend Rate:7.23%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine

prnewswire

·

Sep 11, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/YLD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"YLD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YLD\",,,,,undefined,":{"symbol":"YLD","market":"US","secType":"STK","nameCN":"Principal Active High Yield ETF","latestPrice":19.1899,"timestamp":1771517665071,"preClose":19.2,"halted":0,"volume":30966,"delay":0,"changeRate":-0.0005260416666665509,"floatShares":25250000,"shares":25250000,"eps":0,"marketStatus":"Trading","change":-0.0101,"latestTime":"02-19 11:14:28 EST","open":19.19,"high":19.2,"low":19.165,"amount":594065.9883600001,"amplitude":0.001823,"askPrice":19.19,"askSize":200,"bidPrice":19.18,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771534800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":19.2,"sharesOutstanding":25250000,"nav":19.103795,"aum":482610641.34,"dividendRate":0.07233,"bidAskSpread":0.000522,"preHourTrading":{"tag":"盘前","latestPrice":19.2,"preClose":19.2,"latestTime":"08:02 EST","volume":2,"amount":38.4,"timestamp":1771506125814,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":19.2,"preClose":19.2,"latestTime":"16:10 EST","volume":13,"amount":249.6,"timestamp":1771449009009,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.854909,"impliedVol":0.1107,"impliedVolPercentile":0.5697},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YLD\",,,,,undefined,":{"symbol":"YLD","floatShares":25250000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.854909,"shares":25250000,"dividePrice":1.388,"high":19.2,"amplitude":0.001823,"preClose":19.2,"low":19.165,"week52Low":17.88,"pbRate":"--","week52High":19.48,"institutionHeld":0,"latestPrice":19.1899,"committee":0.428571,"eps":0,"divideRate":0.07233,"volume":30966,"delay":0,"ttmEps":0,"open":19.19,"prevYearClose":19.005,"prevWeekClose":19.15,"prevMonthClose":19.175,"prevQuarterClose":19.005,"fiveDayClose":19.19,"twentyDayClose":19.19,"sixtyDayClose":18.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/YLD\",params:#limit:5,,,undefined,":[{"date":"2026-02-02","symbol":"YLD","amount":0.115854,"announcedDate":"2026-01-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-02","defaultRemindTime":1770042600000,"name":"Principal Active High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-04","payableDate":"2026-02-02","currency":"USD","dateTimestamp":1770008400000,"payDate":"2026-02-04"},{"date":"2025-12-29","symbol":"YLD","amount":0.138984,"announcedDate":"2025-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-29","defaultRemindTime":1767018600000,"name":"Principal Active High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-29","currency":"USD","dateTimestamp":1766984400000,"payDate":"2025-12-31"},{"date":"2025-12-01","symbol":"YLD","amount":0.118474,"announcedDate":"2025-11-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-01","defaultRemindTime":1764599400000,"name":"Principal Active High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-03","payableDate":"2025-12-01","currency":"USD","dateTimestamp":1764565200000,"payDate":"2025-12-03"},{"date":"2025-11-03","symbol":"YLD","amount":0.117748,"announcedDate":"2025-10-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-03","defaultRemindTime":1762180200000,"name":"Principal Active High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-05","payableDate":"2025-11-03","currency":"USD","dateTimestamp":1762146000000,"payDate":"2025-11-05"},{"date":"2025-10-01","symbol":"YLD","amount":0.109121,"announcedDate":"2025-09-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-01","defaultRemindTime":1759325400000,"name":"Principal Active High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-10-01","currency":"USD","dateTimestamp":1759291200000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"YLD\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-01","recordDate":"2016-03-03","paymentDate":"2016-03-07","value":0.1477239,"currency":"USD"},{"executeDate":"2016-04-01","recordDate":"2016-04-05","paymentDate":"2016-04-07","value":0.1274369,"currency":"USD"},{"executeDate":"2016-05-02","recordDate":"2016-05-04","paymentDate":"2016-05-06","value":0.1333339,"currency":"USD"},{"executeDate":"2016-06-01","recordDate":"2016-06-03","paymentDate":"2016-06-07","value":0.1333339,"currency":"USD"},{"executeDate":"2016-07-01","recordDate":"2016-07-06","paymentDate":"2016-07-08","value":0.0752768,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"YLD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"YLD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2566517559","title":"Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2566517559","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566517559?lang=en_us&edition=fundamental","pubTime":"2025-09-11 14:56","pubTimestamp":1757573760,"startTime":"0","endTime":"0","summary":"Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress , including three oral presentations on eptinezumab  and Lu AG09222 . Patients treated with eptinezumab experienced sustained reductions in migraine symptom and burden, including long-term reduction in monthly migraine days  and improvements in patient-reported outcomes1,2. In the phase 4 RESOLUTION trial,7 the early, clinically meaningful improvements in migraine symptom and burden observed during the initial placebo-controlled period were sustained during the open-label extension period.Around 50% of patients achieved a ≥50% reduction from baseline in monthly migraine days  and achieved approximately nine days fewer MMDs at the end of the 12 week OLE, compared to baseline at the start of the RESOLUTION trial .1. In the trial the symptom reduction observed within the first 12 weeks of treatment wi","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lundbeck-showcases-new-clinical-migraine-data-including-long-term-preventive-effectiveness-of-vyepti-eptinezumab-in-patients-severely-impacted-by-migraine-302553653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK7104","SG9999014005.SGD","BK4201","SG9999014021.USD","BK4532","YLD","BK4162","BK4154","BK4585","MOH","IHC","MOH.AU","BK4588","SG9999014013.SGD","EC"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}]}}